FDA取消核心药物咨询委员会会议Biohaven(BHVN.US)盘前大涨超10%

智通财经08-22

智通财经APP获悉，此前，美国食品药品监督管理局(FDA)取消了原计划就Biohaven(BHVN.US)核心药物troriluzole上市申请召开的咨询委员会(AdCom)会议，该股美股周五盘前大幅上涨，截至发稿，该股上涨12.3%。今年年初，这家总部位于康涅狄格州纽黑文的生物科技公司针对脊髓小脑共济失调(一类罕见神经退行性疾病)的troriluzole新药申请(NDA)获得了FDA的优先审评...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2561474544?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-22 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561474544","market":"sh","top_or_hot":-1,"title":"FDA取消核心药物咨询委员会会议Biohaven(BHVN.US)盘前大涨超10%","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，此前，美国食品药品监督管理局(FDA)取消了原计划就Biohaven(BHVN.US)核心药物troriluzole上市申请召开的咨询委员会(AdCom)会议，该股美股周五盘前大幅上涨，截至发稿，该股上涨12.3%。今年年初，这家总部位于康涅狄格州纽黑文的生物科技公司针对脊髓小脑共济失调(一类罕见神经退行性疾病)的troriluzole新药申请(NDA)获得了FDA的优先审评...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1333818.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA取消核心药物咨询委员会会议Biohaven(BHVN.US)盘前大涨超10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA取消核心药物咨询委员会会议Biohaven(BHVN.US)盘前大涨超10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-22 20:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1333818.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，此前，美国食品药品监督管理局(FDA)取消了原计划就Biohaven(BHVN.US)核心药物troriluzole上市申请召开的咨询委员会(AdCom)会议，该股美股周五盘前大幅上涨，截至发稿，该股上涨12.3%。今年年初，这家总部位于康涅狄格州纽黑文的生物科技公司针对脊髓小脑共济失调(一类罕见神经退行性疾病)的troriluzole新药申请(NDA)获得了FDA的优先审评...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1333818.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1333818.html","article_id":"2561474544","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561474544","pubTimestamp":1755865917,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，此前，美国食品药品监督管理局取消了原计划就Biohaven核心药物troriluzole上市申请召开的咨询委员会会议，该股美股周五盘前大幅上涨，截至发稿，该股上涨12.3%。5月，FDA神经科学办公室延长了审评周期，以评估该公司为回应机构要求而提交的补充材料，并决定召开咨询委员会会议讨论该新药申请。该公司仍预计，美国食品药品监督管理局将在2025年第四季度对其递交的新药上市申请做出审批决定。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","BK4139":"生物科技"},"translate_title":"FDA cancels core drug advisory committee meeting Biohaven (BHVN.US) rose more than 10% before the market opened","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":1},"content_text":"智通财经APP获悉，此前，美国食品药品监督管理局(FDA)取消了原计划就Biohaven(BHVN.US)核心药物troriluzole上市申请召开的咨询委员会(AdCom)会议，该股美股周五盘前大幅上涨，截至发稿，该股上涨12.3%。今年年初，这家总部位于康涅狄格州纽黑文的生物科技公司针对脊髓小脑共济失调(一类罕见神经退行性疾病)的troriluzole新药申请(NDA)获得了FDA的优先审评资格。5月，FDA神经科学办公室延长了审评周期，以评估该公司为回应机构要求而提交的补充材料，并决定召开咨询委员会会议讨论该新药申请。在周五提交给美国证券交易委员会(SEC)的文件中，Biohaven指出，FDA已于8月21日通知该审评不再需要召开咨询委员会会议。Biohaven是Biohaven Pharmaceutical的分拆企业，2022年，辉瑞(PFE.US)收购了主营偏头痛药物的Biohaven Pharmaceutical之后，Biohaven作为独立实体被拆分出来。该公司仍预计，美国食品药品监督管理局(FDA)将在2025年第四季度对其递交的新药上市申请(NDA)做出审批决定。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2561474544","isCrawlerRequest":true}